Soleno Therapeutics, Inc. Common Stock (SLNO) is a publicly traded Healthcare sector company. As of May 21, 2026, SLNO trades at $53.01 with a market cap of $2.76B and a P/E ratio of 132.53. SLNO moved +0.01% today. Year to date, SLNO is +14.52%; over the trailing twelve months it is -29.39%. Its 52-week range spans $29.43 to $90.32. Analyst consensus is neutral with an average price target of $61.00. Rallies surfaces SLNO's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Halper Sadeh Targets Soleno Therapeutics $53 Per Share Sale to Neurocrine: Soleno Therapeutics shareholders could challenge its $53 cash sale to Neurocrine, claiming insiders may receive outsized benefits and deal terms could deter competing bids. Halper Sadeh LLC is investigating, offering contingent-fee legal representation to seek higher consideration or additional disclosures.
| Metric | Value |
|---|---|
| Price | $53.01 |
| Market Cap | $2.76B |
| P/E Ratio | 132.53 |
| EPS | $0.40 |
| Dividend Yield | 0.00% |
| 52-Week High | $90.32 |
| 52-Week Low | $29.43 |
| Volume | 0 |
| Avg Volume | 0 |
| Revenue (TTM) | $190.41M |
| Net Income | $20.89M |
| Gross Margin | 98.58% |
12 analysts cover SLNO: 0 strong buy, 1 buy, 11 hold, 0 sell, 0 strong sell. Consensus rating is neutral. Average price target: $61.00.